PRO-CTCAE vs REQUITE: a comparison of two patient reported outcome (PRO) measurement tools in a lung cancer population

Jordan, Tommye; Califano, Raffaele; Coote, J.; Falk, S.; Harris, Margaret; Mistry, Hitesh; Taylor, Peter C; Woolf, David; Faivre‐Finn, C.

doi:10.1016/s0169-5002(19)30189-8

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discrepancy between patient-reported toxicities and those assessed by clinicians using the CTCAE can be attributed to several factors. Evidence suggests that clinician-reported adverse events may miss or underreport up to 50% of symptoms that patients experience during treatment [62]. Clinicians might not fully recognize or document all treatment-related adverse events, especially more subjective ones like fatigue, depression, and sleep disturbances [62].…”

Section: Discussionmentioning

confidence: 99%

“…Evidence suggests that clinician-reported adverse events may miss or underreport up to 50% of symptoms that patients experience during treatment [62]. Clinicians might not fully recognize or document all treatment-related adverse events, especially more subjective ones like fatigue, depression, and sleep disturbances [62]. In conclusion, both PROs and clinician-reported chemotoxicity provide valuable and complementary insights.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotoxicity and Associated Risk Factors in Colorectal Cancer: A Systematic Review and Meta-Analysis

Han,

Ning,

Burd

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) patients experienced multiple chemotoxicity affecting treatment compliance, survival, and quality of life (QOL). Prior research shows clinician-reported chemotoxicity (i.e., grading scales or diagnostic codes) predicts rehospitalization and cancer survival. However, a comprehensive synthesis of clinician-reported chemotoxicity is still lacking. Objectives: We conducted a systematic review and meta-analysis to determine the chemotoxicity's prevalence and risk factors in CRC. Methods: A systematic search from 2009 to 2024 yielded 30 studies for review, with 25 included in the meta-analysis. Results: Pooled prevalences of overall, non-hematological, and hematological moderate-to-severe toxicities were 45.7%, 39.2%, and 25.3%, respectively. The most common clinician-reported chemotoxicities were gastrointestinal (GI) toxicity (22.9%) and neuropathy or neutropenia (17.9%). Significant risk factors at baseline were malnutritional status, frailty, impaired immune or hepato-renal functions, short telomere lengths, low gut lactobacillus levels, age, female sex, aggressive chemotherapy, and low QOL. Age was associated with neutropenia (β: -1.44) and GI toxicity (β:1.85) (Ps 65 y.o.) had higher prevalences of overall (OR: 1.14) and GI (OR: 1.65) toxicities, but a lower prevalence of neutropenia (OR: 0.65) than younger adults (Ps

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%